XML 50 R52.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Collaboration and License Agreements - Additional Information 3 (Detail) (USD $) | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended
--- | --- | --- | --- | ---
Dec. 31, 2014 | Nov. 30, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012
License And Collaboration Agreements [Line Items] |  |  |  |  |
Deferred revenue, Current | $ 14,248,000 us-gaap_DeferredRevenueCurrent |  | $ 20,267,000 us-gaap_DeferredRevenueCurrent |  |
Change in accounting estimate, current year impact | 3,700,000 mgnx_ChangeInAccountingEstimateCurrentYearImpact |  |  |  |
Deferred revenue, Long-term liabilities | 16,472,000 us-gaap_DeferredRevenueNoncurrent |  | 7,136,000 us-gaap_DeferredRevenueNoncurrent |  |
Servier [Member] |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |
Collaboration agreement date | November 2011 |  |  |  |
Nonrefundable upfront payment |  | 20,000,000 mgnx_NonRefundableUpFrontPayment / us-gaap_CounterpartyNameAxis = mgnx_ServierMember |  |  |
Expected period of development | 27 months |  |  |  |
Recognized revenue under agreement | 700,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_ServierMember |  | 21,300,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_ServierMember | 9,100,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_ServierMember |
Milestone payment |  |  | 10,000,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = mgnx_ServierMember |  |
Deferred revenue, Current | 100,000 us-gaap_DeferredRevenueCurrent / us-gaap_CounterpartyNameAxis = mgnx_ServierMember |  | 900,000 us-gaap_DeferredRevenueCurrent / us-gaap_CounterpartyNameAxis = mgnx_ServierMember |  |
Servier [Member] | Second Right to Develop Collaboration [Member] |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |
Collaboration agreement date | September 2012 |  |  |  |
Nonrefundable upfront payment |  |  |  |  | 20,000,000 mgnx_NonRefundableUpFrontPayment / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember
Expected period of development | 29 months |  |  |  |
Recognized revenue under agreement | 16,700,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  | 8,600,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember | 2,000,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |
Milestone payment | 5,000,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  | 0 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember | 0 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |
Deferred revenue, Current | 3,300,000 us-gaap_DeferredRevenueCurrent / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  | 8,600,000 us-gaap_DeferredRevenueCurrent / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |
Option exercise fee | 15,000,000 mgnx_OptionExerciseFee / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |  |  |
Offset to research and development costs under collaboration arrangement | 1,000,000 mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  | 0 mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember | 0 mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |
Option exercise fee recognition period | 82 months |  |  |  |
Collaboration receivable, included in accounts receivable | 800,000 mgnx_CollaborationAgreementConsiderationReceivable / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |  |  |
Number of milestones achieved | 2 mgnx_NumberOfMilestonesAchieved / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |  |  |
Review period | 30 days |  |  |  |
Deferred revenue | 17,700,000 us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  | 9,400,000 us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |
Deferred revenue, Long-term liabilities | 14,400,000 us-gaap_DeferredRevenueNoncurrent / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  | 800,000 us-gaap_DeferredRevenueNoncurrent / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |
Servier [Member] | Scenario, Adjustment [Member] |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |
Expected period of development | 42 months |  |  |  |
Servier [Member] | Scenario, Adjustment [Member] | Second Right to Develop Collaboration [Member] |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |
Expected period of development | 75 months |  |  |  |
Servier [Member] | Maximum [Member] |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |
Additional license grant fees | 30,000,000 mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_RangeAxis = us-gaap_MaximumMember |  |  |  |
Clinical milestone payments | 47,000,000 mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_RangeAxis = us-gaap_MaximumMember |  |  |  |
Regulatory milestone payments | 140,000,000 mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_RangeAxis = us-gaap_MaximumMember |  |  |  |
Sales milestone payments | 208,000,000 mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_RangeAxis = us-gaap_MaximumMember |  |  |  |
Servier [Member] | Maximum [Member] | Second Right to Develop Collaboration [Member] |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |
Additional license grant fees | 65,000,000 mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_RangeAxis = us-gaap_MaximumMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |  |  |
Clinical milestone payments | 98,000,000 mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_RangeAxis = us-gaap_MaximumMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |  |  |
Regulatory milestone payments | 300,000,000 mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_RangeAxis = us-gaap_MaximumMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |  |  |
Sales milestone payments | 630,000,000 mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_RangeAxis = us-gaap_MaximumMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |  |  |
Clinical milestone payments under agreement | $ 5,000,000 mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance / us-gaap_CounterpartyNameAxis = mgnx_ServierMember / us-gaap_RangeAxis = us-gaap_MaximumMember / us-gaap_TypeOfArrangementAxis = mgnx_SecondRightToDevelopCollaborationMember |  |  |  |

X
- Definition Additional Clinical Milestone Potential Payments Under Agreement + References No definition available. + Details
Name: | mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential license grant fees available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional potential milestone payments receivable upon new drug application acceptance. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disclosure of the effect of a change in accounting estimate on current year operations. + References No definition available. + Details
Name: | mgnx_ChangeInAccountingEstimateCurrentYearImpact
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement Consideration Receivable + References No definition available. + Details
Name: | mgnx_CollaborationAgreementConsiderationReceivable
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration and license agreement entered date. + References No definition available. + Details
Name: | mgnx_CollaborationAndLicenseAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | us-types:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration arrangement offset to research and development costs. + References No definition available. + Details
Name: | mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | mgnx_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | mgnx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non-refundable up front payment. + References No definition available. + Details
Name: | mgnx_NonRefundableUpFrontPayment
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of clinical milestones achieved during period. + References No definition available. + Details
Name: | mgnx_NumberOfMilestonesAchieved
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment from collaborator upon exercise of option to develop and commercialize product. + References No definition available. + Details
Name: | mgnx_OptionExerciseFee
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Option exercise fee recognition period. + References No definition available. + Details
Name: | mgnx_OptionExerciseFeeRecognitionPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Review period by regulatory authority. + References No definition available. + Details
Name: | mgnx_ReviewPeriodByRegulatoryAuthority
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period over which upfront payment is to be recognized. + References No definition available. + Details
Name: | mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mgnx_ServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |